Mintiply Capital Announces A Strategic Investment in the Billion-Dollar Pharmaceutical Sector

DUBAI, UAE — Mintiply Capital, a leading investment and advisory firm, has announced its latest strategic move into the global pharmaceutical sector. This investment marks a significant expansion of Mintiply’s portfolio, aligning with the firm’s commitment to fostering growth in industries that present robust long-term potential.

Market Potential: A Billion-Dollar Opportunity in Global and Regional Growth

The global pharmaceutical market, valued at approximately US$1,155 billion in 2024, is poised to continue growing at an annual rate of 4.71% through 2029. Notably, the United States remains a global leader in pharmaceutical innovation, projected to generate revenue of US$630.3 billion this year due to its advanced healthcare infrastructure and cutting-edge research capabilities. Oncology drugs, a key sector in this industry, are set to achieve a market volume of US$194.1 billion globally in 2024, reflecting both the sector’s innovation and critical role in healthcare advancement.

Southern Asia’s pharmaceutical market also presents immense promise, particularly as India emerges as a major contributor to global drug manufacturing. In 2024, the region’s market revenue is expected to reach US$18.14 billion, with oncology drugs leading at a volume of US$2.21 billion. This sector’s projected growth rate of 3.22% CAGR through 2029 reflects both rising demand and regional healthcare advancements.

Strategic Reasons Behind Mintiply’s Move into Pharma

Mintiply’s decision to invest in the pharmaceutical sector is based on several strategic factors:

1. Healthcare Innovation and Demand: With ongoing advancements in gene therapy, cell therapy, and nucleic acid therapy, the pharmaceutical sector is positioned to transform the global healthcare landscape. By investing in these next-generation treatments, Mintiply aims to support the evolution of healthcare solutions that can address complex diseases.
2. Increasing Global Healthcare Needs: An aging global population and rising prevalence of chronic illnesses create a growing demand for innovative treatments, particularly in areas such as oncology, diabetes, and cardiovascular disease. This demand presents a stable and growth-driven environment for investors.
3. Strong Regional Growth in Southern Asia: India’s robust domestic market and global role in drug manufacturing make Southern Asia a compelling regional focus. Mintiply’s investment supports not only the growth of the pharma sector in this region but also its broader economic development.
4. Synergies with Mintiply’s Vision for a Diversified Portfolio: This strategic investment aligns with Mintiply’s vision of creating a diversified and resilient portfolio across emerging sectors. By targeting healthcare and pharmaceuticals, Mintiply strengthens its capacity to deliver value to clients while championing impactful industries.

Mintiply Capital’s entry into pharmaceuticals reflects a long-term commitment to industries with a meaningful impact on society. Through this strategic move, Mintiply is not only positioning itself at the forefront of a transformative market but also reinforcing its dedication to empowering businesses that improve lives.

About Mintiply Capital

Mintiply Capital is a leading investment and advisory firm that provides comprehensive services across wealth and asset management, private equity & venture capital, advisory, and digital asset services. To date, Mintiply Capital’s team has managed over US $3.8 billion in assets and facilitated US $480 million in fund arrangements, serving clients across the United States, United Arab Emirates, and Saudi Arabia. The firm’s integrated approach offers clients the tools and insights they need to achieve sustainable growth and financial success.

This article is being provided for educational purposes only. The information contained in this article does not constitute a recommendation from any Mintiply Capital entity to the recipient, and Mintiply Capital is not providing any financial, economic, legal, investment, accounting, or tax advice through this article or to its recipient. Neither Mintiply Capital nor any of its affiliates makes any representation or warranty, express or implied, as to the accuracy or completeness of the statements or any information contained in this article and any liability therefore (including in respect of direct, indirect, or consequential loss or damage) is expressly disclaimed.